KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) EBIT Margin (2016 - 2025)

Novavax (NVAX) has 16 years of EBIT Margin data on record, last reported at 9.67% in Q4 2025.

  • For Q4 2025, EBIT Margin rose 15810.0% year-over-year to 9.67%; the TTM value through Dec 2025 reached 42.75%, up 7924.0%, while the annual FY2025 figure was 40.3%, 7679.0% up from the prior year.
  • EBIT Margin reached 9.67% in Q4 2025 per NVAX's latest filing, up from 252.71% in the prior quarter.
  • Across five years, EBIT Margin topped out at 77.33% in Q1 2025 and bottomed at 386.37% in Q1 2023.
  • Average EBIT Margin over 5 years is 102.77%, with a median of 67.71% recorded in 2023.
  • Peak YoY movement for EBIT Margin: surged 63138bps in 2021, then tumbled -41610bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 371.27% in 2021, then soared by 82bps to 68.24% in 2022, then increased by 8bps to 63.01% in 2023, then crashed by -136bps to 148.43% in 2024, then soared by 107bps to 9.67% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 9.67% in Q4 2025, 252.71% in Q3 2025, and 57.75% in Q2 2025.